Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pulmicort

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

AstraZeneca AZ

AZ prices severe asthma drug Fasenra below competition

The discounted drug will cost $38,000 in the first year

- PMLiVE

First digital medicine approved in the US

The antipsychotic drug has a built-in digital tracking sensor

AstraZeneca AZ

AZ severe asthma drug benralizumab backed by CHMP

The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

Parexel enhances its clinical supplies mobile app

Adds Bluetooth capability to better monitor temperature-sensitive medication

- PMLiVE

Asthma: beyond the blue and the brown

Innovation in respiratory medicine

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

Evotec invests €15m in AI firm Exscientia

Funds will help the Scottish group accelerate growth

- PMLiVE

The Harmony Alliance gathers to battle blood cancer

Uses its big data platform to analyse the disease

- PMLiVE

Tools for the digital world

The next step for the pharma industry

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links